<DOC>
	<DOCNO>NCT01327872</DOCNO>
	<brief_summary>This randomize , open-label , four-group , two-period , replicate design study evaluate effect food within subject variability second generation formulation 20-mg tablet strength , Lots P01008ZZA P01009ZZA , administer single dos 40mg 84 healthy male female subject . The study power detect reduction either within subject variability ( coefficient variation [ CV ] % ) approximately 35 % .</brief_summary>
	<brief_title>Subject Variability Two Lots E5501 Administered Fed Fasted Healthy Subjects</brief_title>
	<detailed_description>This Phase 2 , multi-center , double-blind , randomize , placebo-controlled , dose-ranging , parallel-group study . The PK PK/PD relationship AKR-501 also study . Approximately 65 eligible patient randomize 3:3:3:3:1 ratio double-blinded fashion one five parallel treatment group receive daily dos either AKR-501 2.5 , 5 , 10 20 mg placebo 28 day , respectively . Each AKR-501 dosing group consist 15 patient placebo group consist 5 patient . All study patient evaluate weekly ( Days 3 , 5 , 7 , 14 , 21 28 ) safety , efficacy , ( Days 7 , 14 , 21 , 28 ) AKR-501 pharmacokinetics receive study treatment final assessment safety effectiveness do 2 week last study dose ( Day 42 ) .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Inclusion criterion : Normal healthy male female subject age great equal 18 year less equal 55 year Body mass index great equal 18 less equal 32kg/m2 Screening Platelet count great equal 120x109/L less equal 250x109/L Women childbearing potential must agree use highly effective method contraception , estrogenbased hormonal contraceptive , Randomization Phase study Evidence clinically significant cardiovascular , hepatic , gastrointestinal , renal , respiratory , endocrine , hematologic , neurologic , psychiatric disease abnormality know history gastrointestinal surgery could impact PK study drug Agents associate thrombotic event ( include oral contraceptive ) must discontinue within 30 day first study drug administration Evidence organ dysfunction clinically significant deviation normal medical history , e.g. , history splenectomy History venous arterial thrombotic disease hypercoaguable state Hemoglobin le low limit normal ( LLN ) level ( female 7.1 mmol/L , males 8.1 mmol/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Idiopathic Thrombocytopenia Purpura ( ITP )</keyword>
	<keyword>Acute Chronic Thrombocytopenia Associated Chronic Liver Disease</keyword>
	<keyword>TLD</keyword>
</DOC>